Summary
TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression.
TRODELVY sets a new standard as Europe’s first ADC and first novel therapy in two decades for eligible patients with first-line metastatic triple-negative breast cancer.
Approval was based on ASCENT-03 data demonstrating a highly statistically significant and clinically meaningful progression-free survival benefit for TRODELVY over chemotherapy in PD-(L)1 inhibitor-ineligible patients
The battle within the rapidly growing Trop-2 ADC market is intensifying, where Gilead now faces escalating competition from AstraZeneca/Daiichi Sankyo and Kelun-Bi...
